Skip to main content

Treatment Clinical Trials for Prostate Cancer

Review the prostate cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 176-200 of 308

High Dose Rate Brachytherapy Boost with Ultrahypofractionated Whole Pelvis Proton Radiation Therapy for the Treatment of High or Unfavorable Intermediate Risk Prostate Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
Curcumin in Treating Patients with Prostate Cancer That Was Removed by Surgery
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Focal Therapy Combined with Androgen Deprivation Therapy for the Treatment of Localized Intermediate Risk Prostate Cancer
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
The Effects of Exercise Therapy on Signs of Localized Prostate Cancer in Active Surveillance
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Abiraterone and Prednisone with Standard ADT versus Standard ADT Alone in Treating Prostate Cancer Patients
Status: Active
Location: University of Nebraska Medical Center, Omaha, Nebraska
Enzalutamide and Talazoparib with Androgen Deprivation Therapy for the Treatment of Patients with Prostate Cancer that is Metastatic to the Lymph Nodes at Diagnosis
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High Intensity Focused Ultrasound for the Treatment of Radiorecurrent Localized Prostate Cancer
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer
Status: Active
Location: NYP/Weill Cornell Medical Center, New York, New York
Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment of Prostate Cancer
Status: Active
Location: Mayo Clinic in Arizona, Scottsdale, Arizona
Intraoperative Imaging with Indocyanine Green for the Improvement of Functional Outcomes in Patients with Prostate Cancer
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Nivolumab for the Treatment of DNA Repair-Mutated, Biochemically Recurrent Prostate Cancer, The NivoCure Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Randomized Phase 2 Trial of Flexible and Extended Dosing of 177Lu-PSMA-617 Molecular Radioligand Therapy for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
High-Dose Testosterone (Tc400) followed by Targeted Radioligand Therapy (PSMA-617) for the Treatment of Metastatic Castration Resistant Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
MR-Linac-Guided Stereotactic Body Radiation Therapy with Androgen Deprivation Therapy for the Treatment of Locally Recurrent Prostate Adenocarcinoma
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Alternating High Dose Testosterone and Darolutamide for the Treatment of Metastatic Prostate Cancer Patients who have not Received Treatment, SPIDERMAN Trial
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Carboplatin and Cabazitaxel versus Lutetium-177-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, CATCH-177 Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Evaluation of Zimberelimab, Etrumadenant, Quemliclustat and Stereotactic Body Radiation Therapy for the Treatment of Hormone Sensitive Oligometastatic Prostate Cancer
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Bortezomib for the Treatment of Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion, BORXPTEN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Status: Active
Location: UCHealth University of Colorado Hospital, Aurora, Colorado